Navigation Links
Optimer Pharmaceuticals Announces FDA Acceptance of NDA for Filing and Designation of Priority Review for Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI)
Date:1/24/2011

s our goal of helping patients who are suffering from this disease." 

The NDA is supported by data from the two largest comparative Phase 3 clinical trials ever conducted against vancomycin in CDI. The two fidaxomicin Phase 3 clinical studies were multi-center, randomized, double-blind trials, which enrolled a total of 1,164 adult patients. Patients with confirmed CDI received either fidaxomicin (200 mg q12h) or Vancocin® (125 mg q6h), the only FDA approved product for the treatment of CDI. In both of these studies, fidaxomicin met the primary endpoint of non-inferiority of clinical cure compared to Vancocin. Importantly, in both trials fidaxomicin was statistically superior to Vancocin in reducing recurrences of CDI and in global cure rate.

About Clostridium difficile Infection (CDI)Clostridium difficile infection (CDI), commonly referred to as "C. difficile" or "c-diff", has become a significant medical problem in hospitals, long-term care facilities, and in the community and is estimated to afflict more than 700,000 people each year in the U.S.  It is a serious illness resulting from infection of the inner lining of the colon by C. difficile bacteria, which produce toxins that cause inflammation of the colon, severe diarrhea and, in the most serious cases, death.  Patients typically develop CDI from the use of broad-spectrum antibiotics that disrupt normal gastrointestinal (gut) flora, thus allowing C. difficile bacteria to flourish and produce toxins.

Current therapeutic options for CDI include the off-label use of metronidazole and oral vancomycin, the latter being the only FDA-approved treatment.  However, approximately 20% to 30% of CDI patients who initially respond to these treatments experience a clinical recurrence following cessation of the CDI treatment.

Primary risk factors for CDI include broad-spectrum antibiotic use (such as cephalosporins and
'/>"/>

SOURCE Optimer Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Optimer Pharmaceuticals Receives Production Patent for Lead Product Candidate Fidaxomicin
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. Data From Optimers Second Phase 3 Study of Prulifloxacin Presented at Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
4. Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI)
5. Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
6. Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
7. Optimer Pharmaceuticals Fidaxomicin Marketing Authorization Application Accepted for Review by European Medicines Agency
8. Optimer Pharmaceuticals to Present at September 2010 Investor Conferences
9. Optimer Pharmaceuticals Announces Presentations of Additional Fidaxomicin Phase 3 Data at Upcoming ICAAC Annual Meeting
10. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
11. Optimer Pharmaceuticals to Host Investor and Analyst Event on November 18
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2013)... MECHELEN, Belgium , May 17, 2013 /PRNewswire/ ... ABBV ) announced today an extension of their ... will fund and complete a Phase 2 program in ... into Phase 3.  Upon successful completion of the study, ... million.  The terms of the collaboration extension are in ...
(Date:5/16/2013)... May 16, 2013  Today, the National Patient Advocate ... House of Representatives recently approved a bill that ... charging patients higher out-of-pocket fees for newer, more expensive ... which have more severe side-effects. However, the bill was ... which will continue to be a barrier to patients ...
(Date:5/16/2013)...  Amgen (NASDAQ: AMGN ) will participate in ... 2013, at the Sheraton New York Times Square in ... Eastern Daylight Time. Joseph P. Miletich , ... Amgen, will present at the conference. Live audio of the ... website, www.amgen.com , under Investors. A replay of the ...
Breaking Medicine Technology:AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 2AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 3AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 4AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 5AbbVie and Galapagos Extend GLPG0634 Collaboration to Include Crohn's Disease 6National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 2National Patient Advocate Foundation Responds to N.C. State House Approval of Flawed Cancer Treatment Fairness Bill 3
... June 17 Neurocrine Biosciences, Inc. (Nasdaq: ... worldwide collaboration with Boehringer Ingelheim to research and develop ... II diabetes and other indications.  The companies will work ...  Boehringer Ingelheim is responsible for the global development and ...
... June 17, 2010 The Medical Device practice at,MarketsandMarkets is pleased to ... , India , China (BRIC) 2010 - 2015. , ... Browse in-depth TOC on ... China (BRIC) 2010 - 2015 Market Report. Early buyers will receive 10%,customization ...
Cached Medicine Technology:-- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes 2-- Neurocrine Announces a Second Corporate Collaboration Within Twenty-Four Hours -- Neurocrine Biosciences Announces a Worldwide Collaboration With Boehringer Ingelheim to Research and Develop GPR119 Agonists for Type II Diabetes 3Diagnostic Imaging Markets in Brazil, Russia, India, China (BRIC) 2010 - 2015: MarketsandMarkets 2Diagnostic Imaging Markets in Brazil, Russia, India, China (BRIC) 2010 - 2015: MarketsandMarkets 3Diagnostic Imaging Markets in Brazil, Russia, India, China (BRIC) 2010 - 2015: MarketsandMarkets 4
(Date:5/18/2013)... New York (PRWEB) May 18, 2013 ... mount in courts throughout the country, Bernstein Liebhard LLP ... hip replacement patients often suffer tissue damage before they ... study, which according to Science Daily will appear in ... hip replacement recipients underwent MRI screens of their hips. ...
(Date:5/18/2013)... May 18, 2013 The “Sleep Apnea ... Oximeters, CPAP, Masks, Adaptive Servo-Ventilation (ASV), Oral Appliances, Nasal ... to 2017” analyzes and studies the major market drivers, ... Rest of the World. , Browse , ... 16 Figures , 318 pagesand ...
(Date:5/18/2013)... (PRWEB) May 18, 2013 The Ayurvedic ... ayurvedic education institution in the West. Program is available ... , Ayurveda is a healing modality practiced for over ... it is considered that health begins when an individual ... understanding of their individual needs. Ayurveda aims to heal ...
(Date:5/18/2013)... May 18, 2013 Losing weight remains to ... among the horde of new weight loss products available in ... about. Recent studies about this newest weight loss supplement prove ... body shape. , Garcinia Cambogia is a sub-tropical fruit that ... Eating the fruit can suppress a person’s appetite, while it ...
(Date:5/18/2013)... 18, 2013 The topics that will be ... framework, scrum roles, scrum meetings, scrum artifacts, and scrum simulation ... for attending them. , These trainings are suitable for business ... ideal for those who will be a part of the ... want to explore Agile and Scrum, but are unsure of ...
Breaking Medicine News(10 mins):Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 2Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 3Health News:Metal-on-Metal Hip Implants: Bernstein Liebhard LLP Comments on New Study Finding that Tissue Damage Precedes Pain in Metal-on-Metal Hip Replacement Patients 4Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 2Health News:Sleep Apnea Devices Market to reach $19.72 Billion by 2017 - New Report by MarketandMarkets 3Health News:Ayurveda Training in Mexico Offered by Escuela de Ayurveda de California, a Leading Institution in the West 2Health News:Lose Weight Without Dieting or Exercising with Garcinia Cambogia Select Now Available At HealthCareSupplementz.com 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 2Health News:Affordable Scrum Trainings In Irvine by Conscires Agile Practices 3
... to face obstacles, research shows , TUESDAY, Feb. 16 ... as they seek treatment for post-traumatic stress disorder, researchers ... from the Iraq and Afghanistan wars received diagnoses of ... those completed the recommended treatment of 10 to 12 ...
... , ... spot for efficiency and transformation through the use of social tools. , ... Minneapolis, MN (PRWEB) February 16, ... service, has been named the winner of the Social Business Innovation Awards. The ...
... Women,s Health Initiative (WHI) confirm that combination hormone therapy increases ... Researchers report a trend toward an increased risk of heart ... women who began therapy within 10 years of menopause, and ... hormone therapy more than 10 years after menopause. Analyses ...
... fine, while their docs disagreed , TUESDAY, Feb. 16 (HealthDay ... new survey has found that a majority of Americans believe ... has the problem. , More than 50 percent of respondents ... direction." In contrast, only 17 percent said their own health ...
... ... global sequence databases is growing exponentially, and legal professionals and scientists doing the critical ... sequence information across these databases. The free seminar includes lunch and roundtable discussion., ... (Vocus) February 16, ...
... ... Premier Anesthesia to manage the anesthesia services for its hospital and surgery center. ... Alpharetta, GA (Vocus) ... contracted with Atlanta-based Premier Anesthesia to manage the anesthesia services for its hospital and ...
Cached Medicine News:Health News:BusinessCard2 Wins Social Business Innovation Award 2Health News:BusinessCard2 Wins Social Business Innovation Award 3Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 2Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 3Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 4Health News:Most Americans Think It's Others Who Are Unhealthy 2Health News:Most Americans Think It's Others Who Are Unhealthy 3Health News:GenomeQuest Hosts Seminar Focused On Web-based Searching for Patent Information Across Global Sequence Databases 2Health News:Premier Anesthesia Forges New Partnership with Texas Hospital 2
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: